| Today’s Big NewsMar 13, 2025 |
|
Thursday, April 3, 2025 | 11am ET / 8am PT Join us for an insightful webinar on the latest advancements in cell and gene therapy, focusing on the innovative Cas9-CLIPT (Cleaved, Linearized with Protein Template) technology. Learn more about this groundbreaking technology designed to improve the efficiency of genome editing. Register now.
|
|
| By Fraiser Kansteiner Having spent the better part of the decade grappling with bankruptcy bids and opioid settlements, troubled drugmakers Mallinckrodt and Endo have decided to join forces to create a more flexible company and ultimately spin off their sizeable generics businesses. |
|
|
|
By Conor Hale BVI said the move fully refinances its debt and adds new equity, both from TPG and additional new investors. |
By Angus Liu Synthetic biology specialist Gro Biosciences, born out of the George Church Lab at Harvard, is exploring strategic alternatives only about half a year after raising a series B backed by top venture capital funds, Fierce Biotech has learned. |
By Gabrielle Masson Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, gastrointestinal (GI) and hematology, while pushing the company’s focus on cell therapy to the backburner. |
By Fraiser Kansteiner Following a hard-fought yet limited FDA approval last year, Akebia plans to kick off a phase 3 trial to assess its Vafseo as a potential treatment for anemia in late-stage CKD patients who aren’t on dialysis. |
By Andrea Park Novartis has teamed up with the NFL in a multi-year partnership, marking the first such collaboration between the football league and a pharmaceutical company. |
By Darren Incorvaia The National Institutes of Health is reportedly continuing its grant-canceling spree, now targeting dozens of research projects related to studying vaccine hesitancy and improving vaccine rates. |
By Zoey Becker Niemann-Pick disease type C therapy Miplyffa became commercially available in late November and by the year's end, a total of 109 prescription enrollment forms had been submitted. The company estimates there are around 900 patients with the disease in the U.S. |
By Conor Hale Samsung backed the Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial work and R&D pipeline. |
By James Waldron Artificial intelligence company Hologen AI has committed up to $430 million as part of a multifaceted agreement to help take MeiraGTx’s Parkinson’s disease gene therapy all the way to market. |
Fierce podcastsDon’t miss an episode |
| This week on "The Top Line," we dig into several of the biggest private funding rounds in biotech last year and discuss the shifting VC landscape. |
|
|---|
|
|
|
Wednesday, April 9, 2025 | 10am ET / 7am PTLearn the key steps for successfully entering Japan’s pharmaceutical market. This webinar covers regulatory requirements, compliance strategies, supply chain best practices, and common challenges. Gain expert insights to navigate this high-potential market with confidence. Don’t miss out—register now to secure your spot!
|
|
| WhitepaperRead about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperDiscover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
| WhitepaperDevelop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| |
|
